Research Article
BibTex RIS Cite

HALLUCINATION AND RISK FACTORS IN PATIENTS WITH PARKINSON’S DISEASE

Year 2019, Volume: 21 Issue: 3, 388 - 394, 31.12.2019

Bahar Say Yasemin Ünal Tuğba Tunç Gülnihal Kutlu Ufuk Ergün

https://doi.org/10.24938/kutfd.619939

Abstract

Objective: Hallucination is one of the non-motor symptoms in
Parkinson disease (PD). Several factors may affect the presence of
hallucination. In the present study, we aimed to compare PD patients presenting
with and without hallucinations, to determine risk factors, and to find out
common hallucination types.

Material and Methods: Idiopathic Parkinson patients regarding to UK
Parkinson Disease Society Brain Bank with and without hallucinations were
compared. The patients with psychotic symptoms due to metabolic, infectious, and structural causes were
excluded. Disease severity was evaluated by Unified Parkinson Disease Rating Scale and Hoehn and Yahr staging.
Cognitive status was assessed by Minimental State Examination test. Depression
was diagnosed on the basis of DSM-V Tr. Description of hallucination,
treatment, co-morbidity, sleep disturbances, REM sleep behavioral disorder,
age, gender, scores of test and scale, stage of disease were recorded.

Results: A total of 91 (59 female, 32 male) patients with idiopathic PD were enrolled. The group with hallucinations
(Group 1) had 40 (43.9%) patients and the one without hallucinations (Group 2)
had 51 (54.9%) patients. Total score of Unified
Parkinson Disease Rating Scale was significantly higher in Group 1 than
Group 2 (37.83±16.65; 30.18±14.83; p=0.028). Sleep
disturbances were high in Group 1 (n=24, 60%) when compared to Group 2 (n=14,
27.4%) (p=0.007). The mean duration of
hallucinations was 24.87±56.47 months in Group 1. Twenty-one patients (23.9%)
had visual hallucinations; 15 (16.5%) patients had illusions (minor
hallucinations); and four (4.4%) patients had auditory hallucinations.

Conclusion: Disease severity in Parkinson's disease may be a
factor in the presence of hallucinations. Hallucinations may also occur with
sleep disorders. Minor hallucinations are frequently observed in early stages,
with visual hallucinations being the most common hallucinations that may occur
in every disease stage.

Keywords

Minor hallucination visual hallucination disease severity sleep

Supporting Institution

None

References

  • 1. Tysnes OB, Storstein A. Epidemiology of Parkinson's disease. J Neural Transm (Vienna). 2017;124(8):901-5.
  • 2. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992;55 (3):181-4.
  • 3. Papapetropoulos S, Mash DC. Psychotic symptoms in Parkinson’s disease. From description to etiology. J Neurol. 2005;252(7):753-64.
  • 4. Lee AH, Weintraub D. Psychosis in Parkinson’s disease without dementia: common and comorbid with other non-motor symptoms. Mov Disord. 2012;27(7):858-63.
  • 5. Amerikan Psikiyatri Birliği. Mental Bozuklukların Tanısal ve Sayımsal El Kitabı, Beşinci baskı (DSM-5) (Çev. ed. E. Köroğlu) Hekimler Aankara. Yayın Birliği, 2013.
  • 6. Akbostancı MC, Balaban H, Atbaşoğlu C. Birleşik Parkinson Hastalığı Değerlendirme Ölçeği motor muayene bölümü ve anormal istemsiz hareketler ölçeğinin değerlendiriciler arası güvenilirlik çalışması. Parkinson Hastalığı ve Hareket Bozuklukları Dergisi. 2000;3:7-13.
  • 7. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology. 1967;17(5):427-42.
  • 8. Folstein MF, Folstein SE, McHugh PR. Mini-mental state. A practical method for grading the cognitive state of patients fort the cilinican. J Physchiatr Res. 1975;12(3):189-98.
  • 9. Gungen C, Ertan T, Eker E, Yaşar R, Engin F. Reliability and validity of the standardized minimental state examination in the diagnosis of mild dementia in Turkish population. Turk Psikiyatri Derg. 2002;13(4):273-81.
  • 10. Ramaker C, Marinus J, Stiggelbout AM, Van Hilten BJ. Systematic evaluation of rating scales for impairment and disability in Parkinson’s disease. Mov Disord. 2002;17(5):867-76.
  • 11. Levin J, Hasan A, Höglinger GU. Psychosis in Parkinson's disease: identification, prevention and treatment. J Neural Transm (Vienna). 2016;123(1):45-50.
  • 12. Onofrj M, Espay AJ, Bonanni L, Delli Pizzi S, Sensi SL. Hallucinations, somatic-functional disorders of PD-DLB as expressions of thalamic dysfunction. Mov Disord. 2019;34(8):1100-11.
  • 13. Williams DR, Lees AJ. Visual hallucinations in the diagnosis of idiopathic Parkinson’s disease: a retrospective autopsy study. Lancet Neurol. 2005;4(10):605-10.
  • 14. Factor SA, Molho ES, Podskalny GD, Brown D. Parkinson’s disease: drug-induced psychiatric states. Adv Neurol. 1995;65:115-38.
  • 15. Pagonabarraga J, Martinez-Horta S, Fernández de Bobadilla R, Pérez J, Ribosa-Nogué R, Marín J et al. Minor hallucinations occur in drug-naive Parkinson's disease patients, even from the premotor phase. Mov Disord. 2016;31(1):45-52.
  • 16. Kulisevsky J, Roldan E. Hallucinations and sleep disturbances in Parkinson’s disease. Neurology. 2004;63(3):28-30.
  • 17. Panchal SC, Ondo WG. Treating hallucinations and delusions associated with Parkinson's disease psychosis. Curr Psychiatry Rep. 2018;20(1):3.
  • 18. Fenelon, G. Alves G. Epidemiology of psychosis in Parkinson's disease, J. Neurol. Sci.2010;289(1-2):12-7.
  • 19. Wu DD, Li SH, Jin LY, Jin Y, Cui YY, Zhao H et al. Influencing factors of visual hallucinations in patients with Parkinson's disease and its relationship with sleep disorders. Zhonghua Yi Xue Za Zhi. 2016;96(13):1016-20.
  • 20. Fenelon G, Soulas T, Cleret de Langavant L, Trinkler I, Bachoud-Levi AC. Feeling of presence in Parkinson’s disease. J Neurol Neurosurg Psychiatry 2011;82(11):1219-1224.
  • 21. Fenelon G, Soulas T, Zenashi F, Langavant FC. The changing face of Parkinson's disease associated psychosis: a cross-sectional study based on the new NINDS-NIMH criteria. Mov Disord. 2010;25(6):763-6.
  • 22. Williams DR, Warren JD, Lees AJ. Using the presence of visual hallucinations to differentiate Parkinson's disease from atypical parkinsonism. J Neurol Neurosurg. Psychiatry. 2008;79(6):652-5.
  • 23. Inzelberg R, Kippervasser S, Korczn AD. Auditory hallucinations in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1998;64(4):533-5.
  • 24. Fenelon G, Mahieux F, Huon R, Ziegler M. Hallucinations in Parkinson’s disease. Prevalence, phenomenology and risk factors. Brain. 2000;123(4):733-45.
  • 25. Marsh L, Williams JR, Rocco M, Grill S, Munro C, Dawson TM. Psychiatric comorbidities in patients with Parkinson disease and psychosis. Neurology. 2004;63(2):293-300.
  • 26. Holroyd S, Currie L, Wooten G.F. Prospective study of hallucinations and delusions in Parkinson's disease, J. Neurol. Neurosurg. Psychiatry. 2001;70(6):734-8.

Parkinson Hastalarında Halusinasyon ve Risk Faktörleri

Year 2019, Volume: 21 Issue: 3, 388 - 394, 31.12.2019

Bahar Say Yasemin Ünal Tuğba Tunç Gülnihal Kutlu Ufuk Ergün

https://doi.org/10.24938/kutfd.619939

Abstract

Amaç: Halusinasyon Parkinson
hastalığındaki non-motor semptomlardan biridir. Halusinasyon varlığında birçok risk
faktörü rol oynayabilir. Bu çalışmada halusinasyonu olan ve olmayan Parkinson
hastalarının karşılaştırılması, risk faktörlerinin belirlenmesi, sık görülen
halusinasyon tiplerinin bulunması amaçlandı.

Gereç ve Yöntemler: İngiltere Beyin Bankası
kriterlerine gore idiopatik Parkinson hastalığı tanısı olan hastalarda
halusinasyonu olan ve olmayanlar karşılaştırıldı. Metabolik, enfeksiyöz ve
yapısal nedenlere bağlı psikotik semptomu olan hastalar çalışmaya dahil
edilmedi. Hastalık şiddeti Birleşik Parkinson Hastalığı Değerlendirme Ölçeği ve
Hoehn ve Yahr evrelemesine göre belirlendi. Kognitif durum Minimental Durum
Değerlendirme testi ile değerlendirildi. Depressif duygu durum tanısı DSM-5 ile
konuldu. Mevcut ise halusinasyon tanımlaması, tedavi, komorbidite, uyku
bozuklukları, REM uyku davranış bozukluğu, yaş, cinsiyet, ölçek ve test
skorları ile hastalık evresi kayıt edildi.

Bulgular: Çalışmaya toplam 91 (59 kadın,
32 erkek) idiopatik Parkinson hastası alındı. Halusinasyonu olan grup (Grup 1)
da 40 (%43.9), halusinasyonu olmayan grupta (Grup 2) 52 (%54.9) hasta vardı.
Birleşik Parkinson Hastalığı Değerlendirme Ölçeği toplam skoru Grup 1 de Grup 2
ye göre anlamlı oranda yüksekti (37.83±16.65; 30.18±14.83; p=0.028). Uyku
bozuklukları Grup 2 (n=14, %27.4) ile karşılaştırıldığında Grup 1’de (n=24, %60) anlamlı oranda yüksekti (p=0.007). Halusinasyon süresi
Grup 1’de ortalama 24.87±56.47 aydı. 21 (%23.9) hasta görsel halusinasyon, 15 (%16.5)
hasta illuzyon (minör halusinasyon) ve dört (%4.4) hasta işitsel halusinasyona
sahipti.

Sonuç: Parkinson hastalığında hastalık şiddeti
halusinasyon varlığında etken olabilir. Halusinasyonlar uyku bozuklukları ile
birlikte görülebilir. Minör halusinasyonlar sıklıkla erken evrede izlenirken,
en sık görülen görsel halusinasyon her evrede izlenebilir.

Keywords

Minör halusinasyon görsel halusinasyon hastalık şiddeti uyku

References

  • 1. Tysnes OB, Storstein A. Epidemiology of Parkinson's disease. J Neural Transm (Vienna). 2017;124(8):901-5.
  • 2. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992;55 (3):181-4.
  • 3. Papapetropoulos S, Mash DC. Psychotic symptoms in Parkinson’s disease. From description to etiology. J Neurol. 2005;252(7):753-64.
  • 4. Lee AH, Weintraub D. Psychosis in Parkinson’s disease without dementia: common and comorbid with other non-motor symptoms. Mov Disord. 2012;27(7):858-63.
  • 5. Amerikan Psikiyatri Birliği. Mental Bozuklukların Tanısal ve Sayımsal El Kitabı, Beşinci baskı (DSM-5) (Çev. ed. E. Köroğlu) Hekimler Aankara. Yayın Birliği, 2013.
  • 6. Akbostancı MC, Balaban H, Atbaşoğlu C. Birleşik Parkinson Hastalığı Değerlendirme Ölçeği motor muayene bölümü ve anormal istemsiz hareketler ölçeğinin değerlendiriciler arası güvenilirlik çalışması. Parkinson Hastalığı ve Hareket Bozuklukları Dergisi. 2000;3:7-13.
  • 7. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology. 1967;17(5):427-42.
  • 8. Folstein MF, Folstein SE, McHugh PR. Mini-mental state. A practical method for grading the cognitive state of patients fort the cilinican. J Physchiatr Res. 1975;12(3):189-98.
  • 9. Gungen C, Ertan T, Eker E, Yaşar R, Engin F. Reliability and validity of the standardized minimental state examination in the diagnosis of mild dementia in Turkish population. Turk Psikiyatri Derg. 2002;13(4):273-81.
  • 10. Ramaker C, Marinus J, Stiggelbout AM, Van Hilten BJ. Systematic evaluation of rating scales for impairment and disability in Parkinson’s disease. Mov Disord. 2002;17(5):867-76.
  • 11. Levin J, Hasan A, Höglinger GU. Psychosis in Parkinson's disease: identification, prevention and treatment. J Neural Transm (Vienna). 2016;123(1):45-50.
  • 12. Onofrj M, Espay AJ, Bonanni L, Delli Pizzi S, Sensi SL. Hallucinations, somatic-functional disorders of PD-DLB as expressions of thalamic dysfunction. Mov Disord. 2019;34(8):1100-11.
  • 13. Williams DR, Lees AJ. Visual hallucinations in the diagnosis of idiopathic Parkinson’s disease: a retrospective autopsy study. Lancet Neurol. 2005;4(10):605-10.
  • 14. Factor SA, Molho ES, Podskalny GD, Brown D. Parkinson’s disease: drug-induced psychiatric states. Adv Neurol. 1995;65:115-38.
  • 15. Pagonabarraga J, Martinez-Horta S, Fernández de Bobadilla R, Pérez J, Ribosa-Nogué R, Marín J et al. Minor hallucinations occur in drug-naive Parkinson's disease patients, even from the premotor phase. Mov Disord. 2016;31(1):45-52.
  • 16. Kulisevsky J, Roldan E. Hallucinations and sleep disturbances in Parkinson’s disease. Neurology. 2004;63(3):28-30.
  • 17. Panchal SC, Ondo WG. Treating hallucinations and delusions associated with Parkinson's disease psychosis. Curr Psychiatry Rep. 2018;20(1):3.
  • 18. Fenelon, G. Alves G. Epidemiology of psychosis in Parkinson's disease, J. Neurol. Sci.2010;289(1-2):12-7.
  • 19. Wu DD, Li SH, Jin LY, Jin Y, Cui YY, Zhao H et al. Influencing factors of visual hallucinations in patients with Parkinson's disease and its relationship with sleep disorders. Zhonghua Yi Xue Za Zhi. 2016;96(13):1016-20.
  • 20. Fenelon G, Soulas T, Cleret de Langavant L, Trinkler I, Bachoud-Levi AC. Feeling of presence in Parkinson’s disease. J Neurol Neurosurg Psychiatry 2011;82(11):1219-1224.
  • 21. Fenelon G, Soulas T, Zenashi F, Langavant FC. The changing face of Parkinson's disease associated psychosis: a cross-sectional study based on the new NINDS-NIMH criteria. Mov Disord. 2010;25(6):763-6.
  • 22. Williams DR, Warren JD, Lees AJ. Using the presence of visual hallucinations to differentiate Parkinson's disease from atypical parkinsonism. J Neurol Neurosurg. Psychiatry. 2008;79(6):652-5.
  • 23. Inzelberg R, Kippervasser S, Korczn AD. Auditory hallucinations in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1998;64(4):533-5.
  • 24. Fenelon G, Mahieux F, Huon R, Ziegler M. Hallucinations in Parkinson’s disease. Prevalence, phenomenology and risk factors. Brain. 2000;123(4):733-45.
  • 25. Marsh L, Williams JR, Rocco M, Grill S, Munro C, Dawson TM. Psychiatric comorbidities in patients with Parkinson disease and psychosis. Neurology. 2004;63(2):293-300.
  • 26. Holroyd S, Currie L, Wooten G.F. Prospective study of hallucinations and delusions in Parkinson's disease, J. Neurol. Neurosurg. Psychiatry. 2001;70(6):734-8.
There are 26 citations in total.

Details

Primary Language English
Subjects Health Care Administration
Journal Section ART
Authors

Bahar Say

Yasemin Ünal This is me 0000-0002-6110-9558

Tuğba Tunç This is me 0000-0001-6510-7931

Gülnihal Kutlu 0000-0002-9325-4151

Ufuk Ergün 0000-0002-2664-1549

Publication Date December 31, 2019
Submission Date September 13, 2019
Published in Issue Year 2019 Volume: 21 Issue: 3

Cite

APA Say, B., Ünal, Y., Tunç, T., Kutlu, G., et al. (2019). HALLUCINATION AND RISK FACTORS IN PATIENTS WITH PARKINSON’S DISEASE. Kırıkkale Üniversitesi Tıp Fakültesi Dergisi, 21(3), 388-394. https://doi.org/10.24938/kutfd.619939
AMA Say B, Ünal Y, Tunç T, Kutlu G, Ergün U. HALLUCINATION AND RISK FACTORS IN PATIENTS WITH PARKINSON’S DISEASE. Kırıkkale Uni Med J. December 2019;21(3):388-394. doi:10.24938/kutfd.619939
Chicago Say, Bahar, Yasemin Ünal, Tuğba Tunç, Gülnihal Kutlu, and Ufuk Ergün. “HALLUCINATION AND RISK FACTORS IN PATIENTS WITH PARKINSON’S DISEASE”. Kırıkkale Üniversitesi Tıp Fakültesi Dergisi 21, no. 3 (December 2019): 388-94. https://doi.org/10.24938/kutfd.619939.
EndNote Say B, Ünal Y, Tunç T, Kutlu G, Ergün U (December 1, 2019) HALLUCINATION AND RISK FACTORS IN PATIENTS WITH PARKINSON’S DISEASE. Kırıkkale Üniversitesi Tıp Fakültesi Dergisi 21 3 388–394.
IEEE B. Say, Y. Ünal, T. Tunç, G. Kutlu, and U. Ergün, “HALLUCINATION AND RISK FACTORS IN PATIENTS WITH PARKINSON’S DISEASE”, Kırıkkale Uni Med J, vol. 21, no. 3, pp. 388–394, 2019, doi: 10.24938/kutfd.619939.
ISNAD Say, Bahar et al. “HALLUCINATION AND RISK FACTORS IN PATIENTS WITH PARKINSON’S DISEASE”. Kırıkkale Üniversitesi Tıp Fakültesi Dergisi 21/3 (December 2019), 388-394. https://doi.org/10.24938/kutfd.619939.
JAMA Say B, Ünal Y, Tunç T, Kutlu G, Ergün U. HALLUCINATION AND RISK FACTORS IN PATIENTS WITH PARKINSON’S DISEASE. Kırıkkale Uni Med J. 2019;21:388–394.
MLA Say, Bahar et al. “HALLUCINATION AND RISK FACTORS IN PATIENTS WITH PARKINSON’S DISEASE”. Kırıkkale Üniversitesi Tıp Fakültesi Dergisi, vol. 21, no. 3, 2019, pp. 388-94, doi:10.24938/kutfd.619939.
Vancouver Say B, Ünal Y, Tunç T, Kutlu G, Ergün U. HALLUCINATION AND RISK FACTORS IN PATIENTS WITH PARKINSON’S DISEASE. Kırıkkale Uni Med J. 2019;21(3):388-94.
 Download Cover Image

Bu Dergi, Kırıkkale Üniversitesi Tıp Fakültesi Yayınıdır.